Infinity Pharmaceuticals Inc., of Cambridge, Mass., started a Phase II trial of IPI-926, an oral molecule designed to inhibit Smoothened, in patients with metastatic or locally advanced inoperable chondrosarcoma. The study is expected to enroll more than 100 patients and will compare IPI-926 to placebo, with progression-free survival as the primary endpoint. Secondary endpoints include time to progression, overall survival, overall response rate and response duration. Infinity also reported that the FDA granted orphan drug status of IPI-926 in chondrosarcoma.